Miglustat Accord (Miglustat)

• Miglustat is used as a substrate reduction therapy targeting glycosphingolipid accumulation in lysosomal storage disorders.
• Gaucher disease type 1: reduces glucosylceramide buildup, improving blood counts, spleen and liver size, and bone disease.
• Niemann‑Pick disease type C: decreases synthesis of glycosphingolipids, helping to stabilize neurological function and slow disease progression.

• Miglustat inhibits the enzyme glucosylceramide synthase, the first step in the biosynthesis of glycosphingolipids. By blocking this pathway, the drug lowers the production of glucosylceramide and related lipids, thereby reducing their accumulation in cells affected by lysosomal storage disorders such as Gaucher disease type 1 and Niemann‑Pick disease type C.

Miglustat may cause a range of adverse reactions, from mild to serious. Patients should be aware of both common and less frequent events.

Common Side Effects

• Diarrhea: frequent loose stools, often mild to moderate.
• Nausea: sensation of unease or urge to vomit.
• Weight loss: unintended reduction in body weight.
• Abdominal pain: discomfort or cramping in the stomach area.
• Tremor: mild shaking of hands or limbs.
• Fatigue: feeling unusually tired or weak.

Serious or Rare Side Effects

• Pancreatitis: severe abdominal pain with elevated enzymes.
• Peripheral neuropathy: numbness or tingling in extremities.
• Severe hypersensitivity: rash, swelling, or difficulty breathing.
• Liver enzyme elevation: abnormal liver function tests.
• Depression or mood changes: persistent sadness or anxiety.
• Severe gastrointestinal bleeding: blood in stool or vomiting.

• Before initiating Miglustat therapy, clinicians should consider several safety measures.
• Assess renal function: evaluate baseline kidney parameters and monitor periodically.
• Monitor gastrointestinal tolerance: watch for persistent diarrhea or vomiting.
• Screen for pancreatitis: educate patients on signs of abdominal pain and seek prompt evaluation.
• Avoid in known hypersensitivity: discontinue if allergic reactions occur.
• Pregnancy and lactation: discuss potential risks with a healthcare professional before use.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Miglustat can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid)

• Oral contraceptives: may reduce hormonal effectiveness, increasing risk of unintended pregnancy.
• Strong CYP3A4 inducers (e.g., rifampicin): may lower miglustat exposure, diminishing therapeutic effect.

Moderate Interactions (Monitor Closely)

• Antacids containing aluminum or magnesium: can affect gastrointestinal absorption, adjust timing of administration.
• Levothyroxine: monitor thyroid function tests as absorption may be altered.
• Warfarin: observe INR values for potential changes in anticoagulation control.